Literature DB >> 9182922

Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis.

G F Verheijden1, A W Rijnders, E Bos, C J Coenen-de Roo, C J van Staveren, A M Miltenburg, J H Meijerink, D Elewaut, F de Keyser, E Veys, A M Boots.   

Abstract

OBJECTIVE: To identify a cartilage-derived autoantigen that is relevant to the rheumatoid arthritis (RA) disease process.
METHODS: A DR4 (DRB1*0401) peptide binding motif was used for the selection of potential self reactive peptides within human cartilage glycoprotein-39 (HC gp-39), a protein that is differentially expressed at the site of chronic inflammation. Synthetic peptides accommodating the motif were tested for binding the RA-associated DR4 (DRB1*0401) molecules. High-affinity binders were then tested for their capacity to stimulate peripheral blood mononuclear cell responses in RA patients or healthy donors. To assess the arthritogenic nature of native HC gp-39, the protein was injected into BALB/c mice.
RESULTS: HC gp-39-derived motif-based peptides were selectively recognized by peripheral blood T cells from RA patients. Injection of the intact protein into BALB/c mice resulted in immunity to HC gp-39, which was found to be associated with the development of a chronic, relapsing arthritis. Moreover, inhalation of the protein led to tolerization of antigen-specific T cells and to suppression of HC gp-39-induced arthritis.
CONCLUSION: These data indicate that HC gp-39 is a target of the immune response in RA. Consequently, HC gp-39 is a candidate for antigen-specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182922     DOI: 10.1002/art.1780400616

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  45 in total

Review 1.  Natural and induced regulation of Th1/Th2 balance.

Authors:  N A Mitchison; D Schuhbauer; B Müller
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Antigen-specific T cells in rheumatoid arthritis.

Authors:  Sean R Bennett; Michael T Falta; Jerry Bill; Brian L Kotzin
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

3.  Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases.

Authors:  Anton P Bussink; Dave Speijer; Johannes M F G Aerts; Rolf G Boot
Journal:  Genetics       Date:  2007-08-24       Impact factor: 4.562

4.  Arthritogenicity of collagen type II is increased by chlorination.

Authors:  E Westman; K Lundberg; H Erlandsson Harris
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

5.  Evaluating candidate autoantigens in rheumatoid arthritis.

Authors:  A P Cope; G Sønderstrup
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Perturbation of the T cell repertoire in rheumatoid arthritis.

Authors:  U G Wagner; K Koetz; C M Weyand; J J Goronzy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 7.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

8.  Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Authors:  Xiaolei Tang; David E Yocum; David Dejonghe; Kathryn Nordensson; Douglas F Lake; John Richard
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

9.  BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance.

Authors:  Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

Review 10.  Roles of B cells in rheumatoid arthritis.

Authors:  Gregg J Silverman; Dennis A Carson
Journal:  Arthritis Res Ther       Date:  2003-12-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.